Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus

Ngā tūemi rite

• Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus
  mā: Hemmingsen, Bianca, me ētahi atu.
  I whakaputaina: (2016)
• Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus
  mā: Madsen, Kasper S, me ētahi atu.
  I whakaputaina: (2019)
• Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus
  mā: Kasper Madsen, me ētahi atu.
  I whakaputaina: (2019)
• Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus
  mā: Hemmingsen, Bianca, me ētahi atu.
  I whakaputaina: (2017)
• Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus
  mā: Bianca Hemmingsen, me ētahi atu.
  I whakaputaina: (2017)